NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma Corp. successfully conducted its Annual General Meeting, with shareholders approving all proposed resolutions, re-electing the existing board, and appointing Glenn Ives and John Ruffolo as Chairs of the Board and Audit Committee, respectively. The company, which focuses on developing treatments for nervous system repair, also received shareholder support for amendments to its stock option plan, including an increase in shares reserved for issuance.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
